3 Nov 2026

EMA launches framework to support regulatory acceptance of NAMs

The European Medicines Agency (EMA) has published new guidance outlining how developers of NAMs can engage with regulators to support their acceptance in medicines development. The guidance describes the range of interactions available with EMA, from early discussions through the Innovation Task Force to scientific and qualification advice, helping developers demonstrate that NAMs are scientifically robust and fit for their intended regulatory use. The initiative is part of EMA's broader efforts to accelerate the integration of innovative, human-relevant approaches into medicines regulation while supporting the replacement, reduction and refinement of animal use.

Find out more about EMA's approach to regulatory acceptance of NAMs: Regulatory acceptance of new approach methodologies (NAMs) to reduce animal use testing | European Medicines Agency (EMA)